Pharm
Omalizumab
search
Omalizumab
, rhuMAb-E25, Xolair
See Also
Asthma Biologic
Asthma Management
Severe Asthma
Indications (all required)
See
Severe Asthma
Refractory moderate to
Severe Persistent Asthma
not controlled on
Inhaled Corticosteroid
s
Positive
Allergy Test
ing for perennial inhaled allergen (e.g. mold, pollen, animal dander)
Patients must be age 6 years or older
Mechanism
Recombinant humanized
Monoclonal Antibody
(rhu-MAB)
Blocks IgE binding to
Mast Cell
s and
Basophil
s
Prevents release of
Allergic Reaction
mediators
Dosing
Approved for age >=6 years old
Dose determined by serum IgE level
Usually 150 to 375 mg SQ every 2 to 4 weeks
Must be given in clinical setting with observation
Adverse Effects
Serious and life-threatening
May predispose to malignancy
Anaphylaxis
Requires administration in clinical setting
Reaction may occur >2 hours after injection
Other reactions
Injection site reaction
Upper Respiratory Infection
s (including
Sinusitis
,
Pharyngitis
)
Headache
Alopecia
Musculoskeletal (
Arthralgia
s, myalgias, limb pain)
Efficacy
Reduces
Asthma Exacerbation
s, hospitalizations and
Inhaled Corticosteroid
dosing in
Allergic Asthma
Normansell (2014) Cochrane Database Syst Rev (1):CD003559 +PMID:24414989 [PubMed]
Safety
Pregnancy Category B
Unknown safety in
Lactation
Resources
Omalizumab (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f6a2191-adfb-48b9-9bfa-0d9920479f0d
References
(2020) Drugs for
Asthma
, Med Lett Drug Ther 62: 193-200
Finn (2003) J Allergy Clin Immunol 111:278-84 [PubMed]
Raymond (2023) Am Fam Physician 107(4): 358-68 [PubMed]
Type your search phrase here